LRRK2 and Parkinson disease: To further investigate the effect of CD- and PD-associated LRRK2 mutations on kinase activity, Ken Y. Hui et al. quantified phosphorylation of a newly identified LRRK2 substrate, Ras-related protein 10 (Rab10), and showed that both kinase domain disease-associated mutations (G2019S and N2081D), increased the phosphorylation of Rab10 [69] which stops EHBP1L1-mediated recycling and inhibits PI3K-Akt immunological responses in phagocytic cells [70].